Skip to main content
Premium Trial:

Request an Annual Quote

Swift Biosciences, BillionToOne Partner to Commercialize COVID-19 Test

NEW YORK – Swift Biosciences announced on Monday it will exclusively distribute BillionToOne's test kit for detecting SARS-CoV-2. 

The qSanger-COVID-19 assay, which received Emergency Use Authorization from the US Food and Drug Administration earlier this month, detects SARS-CoV-2 in samples from nasal, nasopharyngeal, and oropharyngeal swabs and has a testing capacity of 1 million tests per day, according to Swift Biosciences. 

The test also uses different instruments and chemicals than other COVID-19 tests, allowing it to avoid supply chain issues that have plagued the pandemic response, according to Swift Bio. It sequences the virus's genome and doesn't require RNA extraction, and it can be adapted at labs with Sanger sequencers, the company said in a statement. Swift CEO Nathan Wood said clinical laboratories can use excess Sanger instruments to perform 3,000 tests per day per instrument.

Financial and other terms of the deal were not disclosed. 

In April, Swift Biosciences provided BillionToOne with 60,000 research-use-only reactions. Swift will lead all worldwide commercial efforts for the test, excluding Brazil, and the test is available for purchase now.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.